F500 anchor accounts · verified roster
25 marquee operators across 21 countries trust VB Engineering with Pharmaceutical engagements.
Engineering for pharma manufacturing under FDA + EMA + WHO scrutiny. GMP-compliant electrical safety, SIL on sterile fill-lines, and HAZOP across API + formulation. Three hero anchor clients · Pfizer + Bayer + Dr. Reddy's.
VB Engineering serves F500 pharmaceutical manufacturers from India HQ across 21 countries. 21 CFR Part 11 + EU GMP + WHO + ISPE GAMP 5 compliance + IEC 61511 SIL on sterile SIS + NFPA 70E + IEEE 1584 Arc Flash across LV + HV distribution. Cleanroom-compatible methodology · US FDA + EU EMA inspection-ready.
5-discipline brownfield engineering · CEng MIE signed across 21 countries.
Pharmaceutical engagements run the international standards stack with industry-specific regulatory overlays per jurisdiction.
Pharmaceutical manufacturing standards. EU + US baseline.
Good Automated Manufacturing Practice. Applied to all process control deliverables.
SIL assessment on sterile fill-line SIS architectures.
Hazard and operability studies on API + formulation.
Cleanroom + controlled environments classification.
Applied on every pharma electrical safety deliverable.
VB Engineering delivers Pharmaceutical engagements across all five disciplines · cross-walked, cross-signed, and structured for native handover to Wistwin.
Country-native Pharmaceutical engagements with jurisdiction-specific standards, regulators, and case studies. Pick your geography.
Primary: NFPA 70E + IEEE 1584 (Arc Flash), IEC 61511 (SIL), IEC 61882 (HAZOP). Industry overlays per the regulatory frameworks stripe. Cross-walked with jurisdiction-specific standards (PESO + DGFASLI + ADNOC SAES + Aramco SAES + OSHA 1910 + EPA RMP) per country.
Anchor accounts include: Bayer + Pfizer + Dr. Reddy's + Aurobindo + Hetero + Natco + Syngene + Amneal. Reviewer panel includes CEng MIE FIE MIET on every Pharmaceutical deliverable.
Yes. The 5-year retainer covers Year 1 initial study, Years 2-5 quarterly site walk-throughs, annual study refresh, and signage refresh per NFPA 70E + IEEE 1584. Country-native overlays applied. CEng / PE signed every annual refresh.
Within 24 hours a named CEng MIE or PE is on the line. 45-minute discovery call. Joint scoping document within 72 hours. Full engineering proposal within 7 calendar days.
VB Engineering is the field practice. Wistwin is the sister Industry 4.0 digital twin SaaS. Every Pharmaceutical engagement is structured for native handover to Wistwin for ongoing platform optimisation.
Tell us what you need · a named Chartered Engineer responds within 24 hours.
Twelve years inside operating pharmaceutical plants. Vial fill-finish lines, oral solid dose suites, biologics and ATMP facilities, API blocks. Aseptic compliance to EU GMP Annex 1 (2023). Cleanroom integrity to ISO 14644. Validation lifecycle to ASTM E2500. Process safety to IEC 61511. Five engineering practices integrated under one stack.
Pharmaceutical manufacturers face six structural pain points: aseptic compliance under the EU GMP Annex 1 (2023) revision, cleanroom HVAC and pressure-cascade integrity under ISO 14644, cross-contamination risk in multi-product facilities under ICH Q9, validation lifecycle under ASTM E2500, process safety for high-potency and solvent operations under IEC 61511, and capacity expansion engineered under live manufacturing without licence variation. Most engineering firms specialise in one or two. We engineer to all six under one stack.
The EU GMP Annex 1 (2023) revision elevated the standard for sterile manufacturing. A documented Contamination Control Strategy is now mandatory. Grade A/B isolators, RABS upgrades, and barrier integrity testing are all in scope. Most facilities are mid-transition.
Annex 1ISO 14644 classification (Grade A through D) demands tight HVAC control. Pressure cascades, recovery rates, viable and non-viable particle monitoring all sit in the regulator audit. CFD modelling and re-qualification studies are required when the room layout changes.
ISO 14644Multi-product facilities face the perpetual question of dedicated versus shared equipment. ICH Q9 quality risk management drives the decision. Cleaning validation, segregation studies, and HEPA cascade design are the engineering deliverables that close the audit finding.
ICH Q9URS, design qualification, FAT, SAT, IQ, OQ, PQ, process validation. The lifecycle is rigorously enforced by FDA, EU, and WHO inspectors. Change control after qualification adds requalification scope. Audit-grade validation engineering is non-negotiable.
ASTM E2500High-potency API suites, solvent-based formulation areas, and hydrogenation blocks demand HAZOP, LOPA, and SIL under IEC 61511. Classified areas to IEC 60079 where flammable solvents operate. ATEX equipment selection. Safety-critical loop assurance.
HAZOP · SILAdding a new line into a running plant means engineering around campaign schedules, cleaning windows, and licence variation timelines. Brownfield expansion needs accurate as-built drawings, integrated simulation, and risk assessment that protects the live product.
BrownfieldThe five VB Engineering practices each become a pharma-specific delivery in this industry. Power studies absorb the cleanroom electrical and arc flash context. LiDAR captures operating fill lines and OSD suites safely. As-built engineering rebuilds P&IDs and HVAC layouts. Lean simulation optimises line throughput and campaign efficiency. Risk and safety closes out HAZOP, SIL, and validation lifecycle support.
Cleanroom-grade electrical. Load flow with HVAC and clean utilities. Short circuit and protection coordination on plant MV/LV. Arc flash to NFPA 70E across MCCs, packing lines, and utility rooms. Motor starting for chillers and AHU sets.
Open 02 · LiDAROperating-plant capture. Fill-finish lines, OSD suites, bioreactor halls, API process blocks, technical interstitial floors, HVAC plant rooms. Capture during planned changeover windows so the campaign keeps running.
Open 03 · As-BuiltP&ID and HVAC rebuild. Process and instrumentation diagrams, HVAC zoning and pressure-cascade drawings, room layouts, equipment GA, equipment lists matched to validation status. The drawing set the regulator can audit against.
Open 04 · SimulationLine throughput and campaign modelling. Fill-line speed and reject simulation. Tablet press, granulation, and coating throughput. Capacity expansion validation. RAM analysis for OEE improvement.
Open 05 · Risk & SafetyHAZOP, SIL, validation support. Process HAZOP on API blocks, formulation, solvent areas. SIL and LOPA under IEC 61511. ATEX classified-area design. Validation lifecycle engineering. 5-year arc flash AMC retainer keeps labels current.
OpenThe European Union Good Manufacturing Practice guidance for the manufacture of sterile medicinal products. The 2023 revision raised the bar significantly: a documented Contamination Control Strategy is now mandatory, barrier technology (isolators, RABS) is the preferred approach, and the cleanroom design must demonstrate Grade A/B/C/D segregation under continuous viable and non-viable monitoring.
The site-wide documented strategy demonstrating that contamination risk is identified, mitigated, and monitored across personnel flow, material flow, environmental monitoring, cleaning, gowning, and equipment. The CCS is the integrating document Annex 1 inspectors test against. It demands cross-functional engineering input from facilities, process, and quality teams.
The lifecycle that proves a pharmaceutical facility, equipment, or process operates as intended. User Requirements Specification, Factory and Site Acceptance Testing, Installation Qualification, Operational Qualification, Performance Qualification, and Process Validation. ASTM E2500 is the modern risk-based approach. Inspector findings against the validation package trigger product recalls.
The pharmaceutical engineering scope in 2026 is shaped by three converging forces: the EU GMP Annex 1 (2023) cascade pushing every sterile facility worldwide toward isolator and barrier technology, the biologics and ATMP investment wave bringing gene therapy, cell therapy, and ADC suites online, and India\'s API resurgence under the PLI scheme and the global China+1 sourcing shift. An engineering partner that addresses all three in one stack reduces vendor count and integration risk. That is the value proposition under every engagement we run.
The 2023 revision raised the bar globally. Every sterile facility supplying the EU, and any facility chasing equivalent regulatory standing in the United States or WHO PQ market, must demonstrate the upgraded Contamination Control Strategy, isolator or RABS technology, and continuous monitoring. The upgrade pipeline runs through 2027.
Annex 1 UpgradeMonoclonal antibodies, gene therapy, cell therapy, mRNA, and antibody-drug conjugates are all building new suite capacity. Single-use bioreactor halls, BSL-2 environments, viral vector facilities, and ADC isolators each demand a different engineering toolkit. The new capacity demands integrated electrical, mechanical, process, and risk engineering.
Biologics · ATMPThe Indian Production Linked Incentive (PLI) scheme, the global China+1 sourcing shift, and the bulk drug parks initiative have made India the centre of API capacity addition. New blocks, hydrogenation suites, classified-area solvent handling, and HAZOP/SIL compliance under IEC 61511 are all in scope. Engineering execution capacity is the bottleneck.
PLI · APIVial fill-finish line of a Tier 1 sterile manufacturer required Annex 1 (2023) compliance upgrade. RABS to isolator transition, refreshed Contamination Control Strategy, HVAC re-qualification, and integrated arc flash study on the upstream MCC.
Biologics CDMO required expansion from 1,000 L to 2,000 L bioreactor capacity within the existing building footprint. Integrated electrical capacity, single-use suite design, HVAC re-balance, BSL-2 segregation, and validation lifecycle support.
Multi-product API and oral solid dose facility required full as-built reconstruction across hydrogenation, formulation, and packing blocks, plus refreshed HAZOP and SIL studies under IEC 61511 for solvent-handling areas. LiDAR scan completed during planned shutdown windows.
Twelve years of brownfield engineering practice inside operating sterile, OSD, biologics, and API plants with 25+ Fortune Global 500 clients including Pfizer, Bayer, Dr. Reddy\'s, and Syngene. Native practice across EU GMP Annex 1 (2023), US FDA 21 CFR, ICH Q7-Q12, ISO 14644, ASTM E2500, and IEC 61511. In-house Chartered Engineers across electrical, mechanical, process, HVAC, instrumentation, and civil. Five engineering practices integrated.
EU GMP Annex 1 (2023) for sterile manufacturing. US FDA 21 CFR Parts 11, 210, 211 for cGMP and electronic records. ICH Q7 through Q12 for quality management. ISO 14644 for cleanroom classification. ASTM E2500 for risk-based validation. ISPE Baseline Guides. NFPA 70E (2024) for electrical safety. IEC 61511 for safety instrumented systems. WHO TRS for prequalification markets.
Yes. Core sub-service. Contamination Control Strategy documentation, RABS-to-isolator transition engineering, Grade A/B/C/D segregation re-design, HVAC re-qualification, continuous monitoring system specification, barrier integrity testing protocols. Studies accepted for EU, MHRA, and WHO PQ inspection.
Yes. Cleanroom HVAC design and re-qualification, pressure cascade design, recovery rate testing, viable and non-viable particle monitoring scheme design, CFD airflow modelling. Studies delivered with full ISO 14644-1 and 14644-2 documentation for inspector audit.
The validation lifecycle (URS, design qualification, FAT, SAT, IQ, OQ, PQ, process validation) proves a facility or equipment operates as intended under cGMP. We engineer and deliver all stages under the ASTM E2500 risk-based approach, integrated with change control and requalification triggers.
Yes. Process HAZOP on hydrogenation suites, solvent-based formulation areas, fermentation halls, and downstream biologics. LOPA and SIL determination under IEC 61511. ATEX classified-area design under IEC 60079 where flammable solvents operate. Studies close insurer and regulator audit findings.
Yes. Cleanroom-compatible LiDAR capture during planned changeover or shutdown windows, with gowning, equipment sanitisation, and documented entry protocols. Output is a survey-grade point cloud usable for as-built P&ID, HVAC zoning, and equipment GA drawings.
Yes. Strong sub-segment. Adding a new line into a running plant requires accurate as-built drawings, integrated electrical and HVAC capacity studies, cross-contamination risk assessment, validation lifecycle planning, and licence variation engineering documentation. Campaign continuity is preserved throughout.
4 to 16 weeks depending on scope. Arc flash study: 4 to 6 weeks. Annex 1 isolator design package: 8 to 12 weeks. Biologics capacity expansion: 10 to 14 weeks. Multi-product HAZOP/SIL refresh: 6 to 10 weeks. Validation lifecycle support: 8 to 16 weeks. Recertification: 3 to 5 year cycle.
India (HQ Hyderabad, including Hyderabad, Vizag, Vadodara, and Bangalore pharma corridors), USA (Houston operations, plus East Coast and West Coast pharma hubs), UK, Singapore, and Australia. Plus additional pharma markets via project delivery or partnership. Country variant pages list specific regulators and approved entity per market.
Vial fill-finish, OSD, biologics, or API. Share your facility data, the trigger that brought you here (Annex 1 upgrade, capacity expansion, validation refresh, HAZOP/SIL, regulator finding), and the country of operation. Within 5 working days, a Chartered Engineer returns a scoped brief with timeline, applicable standards, and a fixed-price proposal.
WhatsApp: Chat with our scoping desk · Email: [email protected] · Offices: Hyderabad HQ · Houston · Dubai